Kyverna Therapeutics Presents First-In-Disease Use Of KYV-101 In Patient With Severe Stiff-Person Syndrome Published In Proceedings Of The National Academy Of Sciences
Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option after failure to respond to conventional therapiesSignificant improvement in walking distance
